Johann Sebastian de Bono

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3369798/publications.pdf

Version: 2024-02-01

819	81,518	797	573
papers	citations	122 h-index	269 g-index

843	843	843	53766
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. Cancer Research, 2022, 81, 1087-1100.	0.4	23
2	Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. European Urology Focus, 2022, 8, 1157-1168.	1.6	26
3	A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. Annual Review of Pharmacology and Toxicology, 2022, 62, 131-153.	4.2	55
4	Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer. Cancer Research, 2022, 82, 221-234.	0.4	6
5	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase <scp>I</scp>/<scp>II</scp> openâ€label, dose escalation study. International Journal of Cancer, 2022, 150, 993-1006.	2.3	28
6	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. European Journal of Cancer, 2022, 160, 24-60.	1.3	12
7	Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. , 2022, 10, e003697.		28
8	Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). Clinical Cancer Research, 2022, 28, 1518-1530.	3.2	41
9	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, The, 2022, 399, 447-460.	6.3	173
10	Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis. Japanese Journal of Clinical Oncology, 2022, 52, 441-448.	0.6	9
11	Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 393-405.	5.1	16
12	BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotypeâ€"Phase 2a interim results.. Journal of Clinical Oncology, 2022, 40, 126-126.	0.8	0
13	TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)â€"Exploration of germline DDR alteration landscape and potential associations with antitumor activity.. Journal of Clinical Oncology, 2022, 40, 157-157.	0.8	2
14	A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer. Molecular Cancer, 2022, 21, 82.	7.9	6
15	Targeting radioresistance and replication fork stability in prostate cancer. JCI Insight, 2022, 7, .	2.3	4
16	53P Assessing the reporting quality of early phase dose-finding trials. Annals of Oncology, 2022, 33, S24.	0.6	5
17	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kî²/î´, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 2257-2269.	3.2	11
18	Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. European Urology, 2022, 82, 22-30.	0.9	34

#	Article	IF	Citations
19	Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligenceâ€“Enabled Studies of Acute Phosphoproteomic Changes. Molecular Cancer Therapeutics, 2022, 21, 1020-1029.	1.9	3
20	Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonistâ€“Treated Prostate Cancers. Molecular Cancer Research, 2022, 20, 841-853.	1.5	3
21	Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer. Cancers, 2022, 14, 51.	1.7	12
22	The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. Clinical Cancer Research, 2022, 28, 860-869.	3.2	4
23	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5â€year followâ€up results from the STAMPEDE randomised trial (NCT00268476). International Journal of Cancer, 2022, 151, 422-434.	2.3	29
24	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	0.9	51
25	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer, 2022, 170, 296-304.	1.3	14
26	Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. European Urology Oncology, 2022, 5, 659-667.	2.6	8
27	Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancerâ€”Prevalence and Current Clinical Practice. Frontiers in Oncology, 2022, 12, .	1.3	3
28	H3K9 methylation drives resistance to androgen receptorâ€“antagonist therapy in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2114324119.	3.3	21
29	Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer. Clinical Cancer Research, 2022, 28, 3104-3115.	3.2	12
30	Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. European Journal of Cancer, 2022, 170, 285-295.	1.3	9
31	Neutropenia, neutrophilia, and neutrophilâ€“lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211000.	1.4	4
32	Abstract CT207: A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a Trispecific HumabodyÂ® T-cell enhancer, in patients with PSMA+ advanced and/or metastatic solid tumors (POTENTIA). Cancer Research, 2022, 82, CT207-CT207.	0.4	1
33	Clinical activity of <scp>CCâ€90011</scp>, an oral, potent, and reversible <scp>LSD1</scp> inhibitor, in advanced malignancies. Cancer, 2022, 128, 3185-3195.	2.0	10
34	Tolerability of [¹⁷⁷Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.. Journal of Clinical Oncology, 2022, 40, 5047-5047.	0.8	1
35	A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.. Journal of Clinical Oncology, 2022, 40, TPS2691-TPS2691.	0.8	5
36	Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial.. Journal of Clinical Oncology, 2022, 40, 5056-5056.	0.8	4

#	Article	IF	Citations
37	Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer. Clinical Cancer Research, 2022, 28, 3509-3525.	3.2	11
38	Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?. European Urology Focus, 2021, 7, 752-763.	1.6	9
39	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. European Urology, 2021, 79, 200-211.	0.9	76
40	Characterizing CDK12-Mutated Prostate Cancers. Clinical Cancer Research, 2021, 27, 566-574.	3.2	50
41	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. Cancer Discovery, 2021, 11, 80-91.	7.7	148
42	A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. British Journal of Cancer, 2021, 124, 391-398.	2.9	10
43	Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Cancer Research, 2021, 27, 438-446.	3.2	21
44	AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification. Cancer Treatment and Research Communications, 2021, 28, 100218.	0.7	2
45	Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discovery, 2021, 11, 1118-1137.	7.7	124
46	Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation â€“ a Single Unit Experience. Cancer Treatment and Research Communications, 2021, 27, 100309.	0.7	2
47	CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.. Journal of Clinical Oncology, 2021, 39, 161-161.	0.8	3
48	PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 13-13.	0.8	16
49	SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)â€"A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.. Journal of Clinical Oncology, 2021, 39, 107-107.	0.8	1
50	Putative biomarkers of response to anti-PD-1 therapy in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 155-155.	0.8	0
51	Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. Clinical Cancer Research, 2021, 27, 2340-2351.	3.2	10
52	Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.. Journal of Clinical Oncology, 2021, 39, 27-27.	0.8	17
53	Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024. European Urology, 2021, 79, e83-e84.	0.9	0
54	Prostate-specific Membrane Antigen Theranostics for Prostate Cancer Care: A Need to Prove Clinical Utility. European Urology Focus, 2021, 7, 231-233.	1.6	3

#	Article	IF	Citations
55	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. Lancet Oncology, The, 2021, 22, 298-301.	5.1	11
56	Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. Japanese Journal of Clinical Oncology, 2021, 51, 1287-1297.	0.6	1
57	Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study. Cancers, 2021, 13, 1284.	1.7	6
58	Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. Nature Reviews Clinical Oncology, 2021, 18, 454-467.	12.5	11
59	7O Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Annals of Oncology, 2021, 32, S4.	0.6	0
60	Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibodyâ€“Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clinical Cancer Research, 2021, 27, 3602-3609.	3.2	20
61	RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease. Cancer Discovery, 2021, 11, 2334-2353.	7.7	40
62	An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. ESMO Open, 2021, 6, 100089.	2.0	4
63	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer Discovery, 2021, 11, 2812-2827.	7.7	78
64	Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. Oncologist, 2021, 26, e1179-e1188.	1.9	2
65	Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5013-5013.	0.8	12
66	A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.. Journal of Clinical Oncology, 2021, 39, TPS3153-TPS3153.	0.8	16
67	Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor.. Journal of Clinical Oncology, 2021, 39, 2562-2562.	0.8	11
68	Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.. Journal of Clinical Oncology, 2021, 39, 5047-5047.	0.8	1
69	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. Cancers, 2021, 13, 2334.	1.7	9
70	Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, TPS5088-TPS5088.	0.8	8
71	Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e190-e202.	1.8	9
72	CD38 in Advanced Prostate Cancers. European Urology, 2021, 79, 736-746.	0.9	21

#	Article	IF	Citations
73	HER3 expression and MEK activation in non-small-cell lung carcinoma. Lung Cancer Management, 2021, 10, LMT48.	1.5	7
74	The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat. Canadian Urological Association Journal, 2021, 15, E623-E629.	0.3	4
75	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet, The, 2021, 398, 131-142.	6.3	167
76	Abstract CT027: TALAPRO-1 final data: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin and zygosity. , 2021, , .		0
77	A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3KÎ² Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 5248-5257.	3.2	15
78	Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. European Urology, 2021, 80, 243-253.	0.9	28
79	641TiP Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H. Annals of Oncology, 2021, 32, S670-S671.	0.6	0
80	612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients. Annals of Oncology, 2021, 32, S652-S653.	0.6	8
81	580P TALAPRO-1: Talazoparib (TALA) monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) - Exploration of non-DDR mutational landscape and potential associations with antitumor activity. Annals of Oncology, 2021, 32, S630-S631.	0.6	1
82	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 1250-1264.	5.1	159
83	958O Coordinated activation of antitumor responses of g9d2 and CD8 T-cells by targeting BTN3A with ICT01 in patients with solid tumors: EVICTION trial. Annals of Oncology, 2021, 32, S829-S830.	0.6	0
84	Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). Targeted Oncology, 2021, 16, 613-623.	1.7	6
85	647TiP PSMAddition: A phase III trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer. Annals of Oncology, 2021, 32, S673-S675.	0.6	3
86	576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Annals of Oncology, 2021, 32, S627-S628.	0.6	8
87	725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer. Annals of Oncology, 2021, 32, S728.	0.6	6
88	648TiP PSMAfore: A phase III study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naÃ¯ve patients with mCRPC. Annals of Oncology, 2021, 32, S675-S676.	0.6	4
89	581P Patient (pt) reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1. Annals of Oncology, 2021, 32, S631-S632.	0.6	0
90	73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis. Annals of Oncology, 2021, 32, S387.	0.6	8

#	Article	IF	Citations
91	611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study. Annals of Oncology, 2021, 32, S651-S652.	0.6	4
92	Lutetium-177â€“PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2021, 385, 1091-1103.	13.9	1,042
93	Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT). BMJ Open, 2021, 11, e049217.	0.8	2
94	560TiP A phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations. Annals of Oncology, 2021, 32, S617.	0.6	3
95	614P Circulating tumor cell (CTC) morphologic sub-types present prior to treatment in the CARD trial identify therapy resistance. Annals of Oncology, 2021, 32, S653-S654.	0.6	2
96	640TiP Phase Ib/II trial of pembrolizumab (pembro) + lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F. Annals of Oncology, 2021, 32, S669-S670.	0.6	0
97	585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology, 2021, 32, S635-S636.	0.6	1
98	522P Risk mitigation of ocular toxicities due to antibody drug conjugates (ADCs) in novel early-phase clinical trials. Annals of Oncology, 2021, 32, S590.	0.6	1
99	Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. European Urology, 2021, 80, 497-506.	0.9	16
100	Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARDÂstudy. ESMO Open, 2021, 6, 100241.	2.0	13
101	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science, 2021, 374, 216-224.	6.0	135
102	Development of ICT01, a first-in-class, anti-BTN3A antibody for activating VÎ³9VÎ´2 T cellâ€“mediated antitumor immune response. Science Translational Medicine, 2021, 13, eabj0835.	5.8	49
103	HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Research, 2021, 81, 6207-6218.	0.4	25
104	Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. European Urology Oncology, 2020, 3, 540-543.	2.6	13
105	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. European Urology Oncology, 2020, 3, 176-182.	2.6	19
106	Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). Investigational New Drugs, 2020, 38, 1117-1128.	1.2	10
107	Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational New Drugs, 2020, 38, 1096-1107.	1.2	11
108	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI Cancer Spectrum, 2020, 4, pkz093.	1.4	126

#	Article	IF	Citations
109	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. JAMA Oncology, 2020, 6, 217.	3.4	18
110	Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clinical Cancer Research, 2020, 26, 1220-1228.	3.2	77
111	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Journal of Clinical Oncology, 2020, 38, 395-405.	0.8	450
112	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 162-174.	5.1	450
113	KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC). European Urology Open Science, 2020, 19, e871-e872.	0.2	0
114	Prostate Cancer 2020: â€œThe Times They Are aâ€™Changingâ€• Cancer Cell, 2020, 38, 25-27.	7.7	18
115	610O Final overall survival (OS) analysis of PROfound: Olaparib vs physicianâ€™s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Annals of Oncology, 2020, 31, S508.	0.6	7
116	Intermittent schedules of the oral RAFâ€“MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncology, The, 2020, 21, 1478-1488.	5.1	41
117	Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. Journal of Experimental Medicine, 2020, 217, .	4.2	19
118	138P TALAPRO-1: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin. Annals of Oncology, 2020, 31, S294-S295.	0.6	1
119	625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update. Annals of Oncology, 2020, 31, S516-S517.	0.6	4
120	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 383, 2345-2357.	13.9	440
121	A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic. Lancet Oncology, The, 2020, 21, 889-891.	5.1	4
122	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncology, The, 2020, 21, 1513-1525.	5.1	35
123	Targeting defective DNA repair in prostate cancer. Current Opinion in Oncology, 2020, 32, 503-509.	1.1	4
124	LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology, 2020, 31, S1153-S1154.	0.6	28
125	621P Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update. Annals of Oncology, 2020, 31, S513-S514.	0.6	5
126	623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update. Annals of Oncology, 2020, 31, S514-S515.	0.6	3

#	Article	IF	Citations
127	629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study. Annals of Oncology, 2020, 31, S519-S520.	0.6	1
128	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectrum, 2020, 4, pkaa003.	1.4	1
129	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Nonâ€“BRCA1/2-Mutant Cancers. Cancer Discovery, 2020, 10, 1528-1543.	7.7	82
130	Prostate carcinogenesis: inflammatory storms. Nature Reviews Cancer, 2020, 20, 455-469.	12.8	114
131	Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2020, 38, 3195-3204.	0.8	152
132	Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. British Journal of Cancer, 2020, 122, 1324-1332.	2.9	23
133	Elucidating Durable Responses to Immune Checkpoint Inhibition. European Urology, 2020, 78, 639-641.	0.9	3
134	DNA Repair and Prostate Cancer: A Field Ripe for Harvest. European Urology, 2020, 78, 486-488.	0.9	19
135	A phase I dose-escalation study of enzalutamide in combination with theÂAKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. Annals of Oncology, 2020, 31, 619-625.	0.6	54
136	Circulating cell-free DNA: Translating prostate cancer genomics into clinical care. Molecular Aspects of Medicine, 2020, 72, 100837.	2.7	6
137	Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival. British Journal of Cancer, 2020, 122, 801-811.	2.9	52
138	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
139	Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 382, 2091-2102.	13.9	1,327
140	Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. , 2020, 8, e000713.		8
141	Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. Clinical Cancer Research, 2020, 26, 4805-4813.	3.2	12
142	Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation. Metabolomics, 2020, 16, 50.	1.4	2
143	Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. Clinical Cancer Research, 2020, 26, 1965-1976.	3.2	55
144	Genetic Analysis of Circulating Tumour Cells. Recent Results in Cancer Research, 2020, 215, 57-76.	1.8	12

#	Article	IF	Citations
145	2170 Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study. Annals of Oncology, 2020, 31, S1325.	0.6	2
146	First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. British Journal of Cancer, 2020, 123, 1730-1736.	2.9	63
147	316â€...EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A. , 2020, , .		4
148	388â€...Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors. , 2020, 8, A413-A413.		1
149	CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. Journal of Clinical Investigation, 2020, 130, 2435-2450.	3.9	27
150	Genomics of lethal prostate cancer at diagnosis and castration resistance. Journal of Clinical Investigation, 2020, 130, 1743-1751.	3.9	180
151	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. Journal of Clinical Investigation, 2020, 130, 5875-5892.	3.9	40
152	The landscape of RNA polymerase IIâ€“associated chromatin interactions in prostate cancer. Journal of Clinical Investigation, 2020, 130, 3987-4005.	3.9	37
153	BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.. Journal of Clinical Oncology, 2020, 38, 3618-3618.	0.8	6
154	Circulating tumor DNA (ctDNA) dynamics associate with treatment response and radiological progression-free survival (rPFS): Analyses from a randomized phase II trial in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5508-5508.	0.8	10
155	Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5526-5526.	0.8	10
156	Impact of olaparib vs physicianâ€™s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.. Journal of Clinical Oncology, 2020, 38, 5538-5538.	0.8	1
157	Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound.. Journal of Clinical Oncology, 2020, 38, 5539-5539.	0.8	4
158	KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5543-5543.	0.8	17
159	Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.. Journal of Clinical Oncology, 2020, 38, 5544-5544.	0.8	14
160	First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5552-5552.	0.8	15
161	Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.. Journal of Clinical Oncology, 2020, 38, 5559-5559.	0.8	2
162	TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) â€“ updated interim analysis (IA).. Journal of Clinical Oncology, 2020, 38, 5566-5566.	0.8	15

#	Article	IF	Citations
163	KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 100-100.	0.8	34
164	KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 102-102.	0.8	9
165	KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 103-103.	0.8	10
166	PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. Journal of Clinical Oncology, 2020, 38, 134-134.	0.8	6
167	Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.. Journal of Clinical Oncology, 2020, 38, 15-15.	0.8	15
168	Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 182-182.	0.8	13
169	CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.. Journal of Clinical Oncology, 2020, 38, 5569-5569.	0.8	1
170	Pain progression at initiation of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of PROSELICA.. Journal of Clinical Oncology, 2020, 38, 5558-5558.	0.8	0
171	Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.. Journal of Clinical Oncology, 2020, 38, 5550-5550.	0.8	5
172	Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.. Journal of Clinical Oncology, 2020, 38, 5545-5545.	0.8	4
173	Abstract LB-270: Discovery of genomic correlates and tumor purity as an independent clinical factor of poor outcome in advanced prostate cancer lpWGS CNA data. , 2020, , .		1
174	Abstract LB-075: CDK12-mutated lethal prostate cancers: How hot are these tumors. , 2020, , .		0
175	Abstract P1-19-29: An integrated safety analysis of talazoparib monotherapy from five clinical trials (phase 1-3) in advanced cancers. , 2020, , .		0
176	389â€…Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors. , 2020, 8, A414-A414.		0
177	Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clinical Cancer Research, 2019, 25, 928-936.	3.2	232
178	Managing Nonmetastatic Castration-resistant Prostate Cancer. European Urology, 2019, 75, 285-293.	0.9	125
179	Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer. Cell Reports, 2019, 28, 2156-2168.e5.	2.9	129
180	Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. European Urology, 2019, 76, 469-478.	0.9	269

#	Article	IF	Citations
181	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. Molecular Cancer Therapeutics, 2019, 18, 1396-1404.	1.9	14
182	Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer. Journal of Clinical Oncology, 2019, 37, 2182-2184.	0.8	13
183	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology, 2019, 292, 273-286.	3.6	46
184	PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Annals of Oncology, 2019, 30, v881-v882.	0.6	54
185	Androgen Receptor Modulation Optimized for Responseâ€"Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7â€"expressing Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 843-851.	0.9	36
186	Abiraterone in â€œHigh-â€•and â€œLow-riskâ€•Metastatic Hormone-sensitive Prostate Cancer. European Urology, 2019, 76, 719-728.	0.9	142
187	Tisotumab vedotin (TV) in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the full cervical cohort of the phase II innova TV 201 study (NCT02001623). Gynecologic Oncology, 2019, 154, 11-12.	0.6	0
188	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 2506-2518.	13.9	403
189	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. Clinical Cancer Research, 2019, 25, 4624-4633.	3.2	21
190	A decade of clinical development of PARP inhibitors in perspective. Annals of Oncology, 2019, 30, 1437-1447.	0.6	437
191	Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene, 2019, 38, 5700-5724.	2.6	59
192	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 676-685.	0.9	62
193	Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Research, 2019, 79, 2580-2592.	0.4	85
194	PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers. European Urology, 2019, 76, 459-460.	0.9	5
195	Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1â€"2 trial. Lancet Oncology, The, 2019, 20, 383-393.	5.1	131
196	PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Annals of Oncology, 2019, 30, ix188-ix189.	0.6	11
197	Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. European Urology, 2019, 76, 306-312.	0.9	26
198	Immunotherapy for lethal prostate cancer. Nature Reviews Urology, 2019, 16, 69-70.	1.9	20

#	Article	IF	Citations
199	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. European Urology, 2019, 75, 184-192.	0.9	69
200	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. European Urology, 2019, 75, 929-937.	0.9	41
201	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 687-697.	3.2	43
202	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. European Urology, 2019, 75, 88-99.	0.9	333
203	First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 3007-3007.	0.8	24
204	PIPA: A phase Ib study of selective ÃŸ-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancersâ€"Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.. Journal of Clinical Oncology, 2019, 37, 3087-3087.	0.8	4
205	PSMA heterogeneity and DNA repair defects in prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5002-5002.	0.8	2
206	TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.. Journal of Clinical Oncology, 2019, 37, 5005-5005.	0.8	35
207	Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.. Journal of Clinical Oncology, 2019, 37, 5010-5010.	0.8	3
208	Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.. Journal of Clinical Oncology, 2019, 37, 5027-5027.	0.8	7
209	Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5070-5070.	0.8	2
210	A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350).. Journal of Clinical Oncology, 2019, 37, TPS5087-TPS5087.	0.8	2
211	Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 145-145.	0.8	43
212	Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 171-171.	0.8	14
213	Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.. Journal of Clinical Oncology, 2019, 37, 216-216.	0.8	8
214	Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue.. Journal of Clinical Oncology, 2019, 37, 151-151.	0.8	0
215	Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials.. Journal of Clinical Oncology, 2019, 37, e18175-e18175.	0.8	0
216	Distinct radiological patterns of drug-induced pneumonitis (R-DIP) in early-phase clinical trials and predictive factors affecting outcome: A 10-year systematic review from the Royal Marsden Hospital Phase I Drug Development Unit experience.. Journal of Clinical Oncology, 2019, 37, 3088-3088.	0.8	0

#	Article	IF	Citations
217	Abstract PL03-01: Targeting DNA Repair and Defective DNA repair. , 2019, , .		0
218	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359, 920-926.	6.0	1,199
219	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 694.	3.4	46
220	Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). European Urology, 2018, 74, 283-291.	0.9	82
221	Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience. Journal of Neuro-Oncology, 2018, 139, 107-116.	1.4	5
222	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics, 2018, 50, 682-692.	9.4	182
223	Second-generation antiandrogens in nonmetastatic CRPC. Nature Reviews Urology, 2018, 15, 342-344.	1.9	4
224	BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. Cell Reports, 2018, 22, 796-808.	2.9	103
225	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. European Urology, 2018, 73, 687-693.	0.9	99
226	Metastatic Prostate Cancer. New England Journal of Medicine, 2018, 378, 645-657.	13.9	386
227	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	0.9	105
228	Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nature Genetics, 2018, 50, 219-228.	9.4	139
229	Metastatic Prostate Cancer. New England Journal of Medicine, 2018, 378, 1653-1654.	13.9	56
230	The long tail of oncogenic drivers in prostate cancer. Nature Genetics, 2018, 50, 645-651.	9.4	601
231	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). Clinical Cancer Research, 2018, 24, 3149-3162.	3.2	111
232	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European Urology Focus, 2018, 4, 235-244.	1.6	14
233	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	0.9	488
234	Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178â€“211. European Urology, 2018, 73, e32-e33.	0.9	6

#	Article	IF	Citations
235	Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for â‰¥24 weeks in Europe. European Urology, 2018, 74, 37-45.	0.9	86
236	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease. Investigative Radiology, 2018, 53, 96-102.	3.5	36
237	Treatment of Advanced Prostate Cancerâ€"A Review of Current Therapies and Future Promise. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030635.	2.9	128
238	Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clinical Oncology, 2018, 30, 185-191.	0.6	3
239	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. Journal of Clinical Investigation, 2018, 129, 192-208.	3.9	266
240	Reply to M. Horiguchi et al. Journal of Clinical Oncology, 2018, 36, 826-827.	0.8	1
241	Reply to C. Ren et al. Journal of Clinical Oncology, 2018, 36, 2354-2356.	0.8	0
242	EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients. Oncotarget, 2018, 9, 35705-35716.	0.8	70
243	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. Journal of Clinical Investigation, 2018, 128, 4441-4453.	3.9	155
244	Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, The, 2018, 19, e696-e708.	5.1	90
245	Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre. British Journal of Cancer, 2018, 119, 922-927.	2.9	3
246	Can Early Clinical Trials Help Deliver More Precise Cancer Care?. , 2018, , 115-128.		0
247	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. British Journal of Cancer, 2018, 118, 1425-1433.	2.9	72
248	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 280-284.	1.0	33
249	IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature, 2018, 559, 363-369.	13.7	258
250	Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 1187.	3.4	14
251	CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature, 2018, 559, 285-289.	13.7	297
252	Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. Journal of Clinical Oncology, 2018, 36, 572-580.	0.8	187

#	Article	IF	Citations
253	Health economic impact of liquid biopsies in cancer management. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 593-599.	0.7	31
254	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clinical Cancer Research, 2018, 24, 5585-5593.	3.2	113
255	Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). International Journal of Cancer, 2018, 143, 2584-2591.	2.3	68
256	Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. European Journal of Cancer, 2018, 101, 55-61.	1.3	6
257	Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Annals of Oncology, 2018, 29, 1554-1560.	0.6	65
258	Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer. Current Opinion in Supportive and Palliative Care, 2018, 12, 339-343.	0.5	9
259	A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 82, 757-766.	1.1	3
260	Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. Clinical Cancer Research, 2018, 24, 5635-5644.	3.2	88
261	Alternative splicing in prostate cancer. Nature Reviews Clinical Oncology, 2018, 15, 663-675.	12.5	142
262	Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013. European Urology, 2018, 74, e69-e70.	0.9	0
263	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell, 2018, 173, 1770-1782.e14.	13.5	400
264	A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. PLoS ONE, 2018, 13, e0193689.	1.1	20
265	Hypoxia and Noncoding RNAs in Taxane Resistance. Trends in Pharmacological Sciences, 2018, 39, 695-709.	4.0	23
266	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. European Urology Oncology, 2018, 1, 151-159.	2.6	28
267	Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. European Urology Oncology, 2018, 1, 71-77.	2.6	24
268	Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. European Urology, 2018, 73, 727-735.	0.9	55
269	KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5007-5007.	0.8	72
270	Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5013-5013.	0.8	5

#	Article	IF	Citations
271	Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.. Journal of Clinical Oncology, 2018, 36, 5064-5064.	0.8	2
272	Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer.. Journal of Clinical Oncology, 2018, 36, 5070-5070.	0.8	4
273	A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology, 2018, 36, TPS391-TPS391.	0.8	6
274	SOX9 is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition. Oncotarget, 2018, 9, 7604-7615.	0.8	29
275	Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients. Oncotarget, 2018, 9, 19283-19293.	0.8	54
276	Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? Against. European Oncology and Haematology, 2018, 14, 14.	0.0	0
277	Consensus statement on circulating biomarkers for advanced prostate cancer.. Journal of Clinical Oncology, 2018, 36, 299-299.	0.8	1
278	Clinical outcome of patients with germline DNA repair mutations: Results from a retrospective international study.. Journal of Clinical Oncology, 2018, 36, 218-218.	0.8	0
279	Clinical and economic burden of serious adverse events (SAEs) in an early phase trials unit.. Journal of Clinical Oncology, 2018, 36, e18890-e18890.	0.8	0
280	A novel approach to mine the Veterans Administration Informatics and Computing Infrastructure (VINCI) allows one to assess the efficacy of cancer therapies: Abiraterone and enzalutamide in Veterans with metastatic prostate cancer (PC).. Journal of Clinical Oncology, 2018, 36, 6586-6586.	0.8	0
281	The prognostic and predictive value of AR-V7 quantification in mCRPC.. Journal of Clinical Oncology, 2018, 36, 12026-12026.	0.8	0
282	Early changes in PSA and association with outcomes in mCRPC patients.. Journal of Clinical Oncology, 2018, 36, 5063-5063.	0.8	0
283	Abstract 4579: The genetic heterogeneity and the molecular evolution of systemic metastatic castration resistant prostate cancer during therapy. Cancer Research, 2018, 78, 4579-4579.	0.4	1
284	Abstract B017: PARP-1 and E2F1 collaborate to transcriptionally regulate DNA repair factor availability. , 2018, , .		0
285	Abstract B040: Differential impact of RB status on E2F1 reprogramming in human cancer. , 2018, , .		0
286	Abstract IA03: Differential impact of RB pathway status on E2F1 reprogramming and disease progression in human prostate cancer. , 2018, , .		0
287	Abstract A067: Targeting the bromodomain and extra-terminal (BET) family proteins and beyond in metastatic castration-resistant prostate cancer (mCRPC): Overcoming aberrant androgen receptor (AR) signaling. , 2018, , .		0
288	Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma. Blood, 2018, 132, 3237-3237.	0.6	0

#	Article	IF	Citations
289	METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. European Urology, 2017, 71, 81-92.	0.9	230
290	Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. European Urology, 2017, 71, 656-664.	0.9	67
291	Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer and Prostatic Diseases, 2017, 20, 221-227.	2.0	70
292	Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care?. European Urology, 2017, 72, 201-204.	0.9	2
293	Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Lancet Oncology, The, 2017, 18, 473-485.	5.1	67
294	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discovery, 2017, 7, 620-629.	7.7	321
295	Clinical outcomes and survival surrogacy studies of prostateâ€specific antigen declines following enzalutamide in men with metastatic castrationâ€resistant prostate cancer previously treated with docetaxel. Cancer, 2017, 123, 2303-2311.	2.0	32
296	CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. Annals of Oncology, 2017, 28, 1495-1507.	0.6	91
297	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery, 2017, 7, 1006-1017.	7.7	341
298	Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. Clinical Genitourinary Cancer, 2017, 15, e801-e807.	0.9	16
299	Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids. Clinical Genitourinary Cancer, 2017, 15, 678-684.e1.	0.9	16
300	Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. Molecular Cancer Therapeutics, 2017, 16, 2315-2323.	1.9	8
301	Targeting DNA damage response systems to impact cancer care. Current Problems in Cancer, 2017, 41, 247-250.	1.0	2
302	A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3KÎ± Isoform Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2017, 23, 5015-5023.	3.2	65
303	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. New England Journal of Medicine, 2017, 377, 338-351.	13.9	1,315
304	Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. European Journal of Cancer, 2017, 76, 36-44.	1.3	64
305	Clinical Outcomes from Androgen Signalingâ€“directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. European Urology, 2017, 72, 10-13.	0.9	32
306	Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. Radiology, 2017, 284, 88-99.	3.6	45

#	Article	IF	Citations
307	Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelialâ€“Mesenchymal Plasticity in Prostate Cancer. Cancer Research, 2017, 77, 3101-3112.	0.4	68
308	Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. Clinical Genitourinary Cancer, 2017, 15, 610-617.e3.	0.9	25
309	Circulating biomarkers of neuroendocrine prostate cancer: an unmet challenge. BJU International, 2017, 119, 3-4.	1.3	2
310	Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. ESMO Open, 2017, 2, e000101.	2.0	7
311	RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses. British Journal of Cancer, 2017, 117, 954-964.	2.9	14
312	Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer. Value in Health, 2017, 20, 1411-1419.	0.1	7
313	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. Clinical Cancer Research, 2017, 23, 6070-6077.	3.2	30
314	Application of Liquid Biopsies in Cancer Targeted Therapy. Clinical Pharmacology and Therapeutics, 2017, 102, 745-747.	2.3	20
315	Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. Cancer Research, 2017, 77, 4745-4754.	0.4	56
316	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2017, 23, 5981-5992.	3.2	107
317	The molecular underpinnings of prostate cancer: impacts on management and pathology practice. Journal of Pathology, 2017, 241, 173-182.	2.1	36
318	Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033. European Urology, 2017, 71, e11.	0.9	1
319	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of Oncology, 2017, 28, 90-95.	0.6	24
320	Phenotypic diversity of circulating tumour cells in patients with metastatic castrationâ€resistant prostate cancer. BJU International, 2017, 120, E30-E44.	1.3	54
321	DNA Repair in Prostate Cancer: Biology and Clinical Implications. European Urology, 2017, 71, 417-425.	0.9	169
322	Rationale for Modernising Imaging in Advanced Prostate Cancer. European Urology Focus, 2017, 3, 223-239.	1.6	62
323	Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033. European Urology, 2017, 71, e56.	0.9	0
324	The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. Clinical Cancer Research, 2017, 23, 1967-1973.	3.2	46

#	Article	IF	Citations
325	A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2017, 79, 17-27.	1.1	6
326	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology, 2017, 283, 168-177.	3.6	81
327	Enzalutamide in castrationâ€resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer, 2017, 123, 253-262.	2.0	42
328	Heterogeneity of advanced prostate cancer: clinical implications of genomics. Trends in Urology & Men's Health, 2017, 8, 24-27.	0.2	0
329	Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476). Annals of Oncology, 2017, 28, v620.	0.6	6
330	Phase I, open-label, dose-finding study of GSK2636771, a phosphoinositide 3-kinase (PI3K)Î² inhibitor, in combination with enzalutamide in male subjects with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology, 2017, 28, v273.	0.6	1
331	Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20â€‰mg/m2 (C20) vs 25â€‰mg/m2 (C25) in post-docetaxel (D) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology, 2017, 28, v280-v281.	0.6	0
332	Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence enhancement and tumor inhibition in advanced prostate cancer. Annals of Oncology, 2017, 28, v272-v273.	0.6	0
333	A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. PLoS ONE, 2017, 12, e0186106.	1.1	14
334	Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m²) and the Currently Approved Dose (25 mg/m²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancerâ€"PROSELICA. Journal of Clinical Oncology, 2017, 35, 3198-3206.	0.8	218
335	Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital. Annals of Oncology, 2017, 28, v132-v133.	0.6	0
336	Abstract 4679: Mismatch repair defects in lethal prostate cancer. , 2017, , .		3
337	Abstract 993: Diagnostic leukapheresis (DLA): Molecular characterisation and organoid culture of circulating tumor cells (CTC) from metastatic castration resistant prostate cancer (mCRPC). Cancer Research, 2017, 77, 993-993.	0.4	4
338	Differential impact of RB status on E2F1 reprogramming in human cancer. Journal of Clinical Investigation, 2017, 128, 341-358.	3.9	83
339	Clinical outcomes of adolescents and young adults (AYA) with advanced solid tumors participating in phase I trials.. Journal of Clinical Oncology, 2017, 35, 10536-10536.	0.8	1
340	An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.. Journal of Clinical Oncology, 2017, 35, 2503-2503.	0.8	12
341	Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.. Journal of Clinical Oncology, 2017, 35, 2506-2506.	0.8	22
342	A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.. Journal of Clinical Oncology, 2017, 35, 2570-2570.	0.8	12

#	Article	IF	Citations
343	Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5005-5005.	0.8	23
344	Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials.. Journal of Clinical Oncology, 2017, 35, 5007-5007.	0.8	3
345	Clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with a post-treatment circulating tumor cell (CTC) of 0 vs CTC > 0: Post hoc analysis of COU-AA-301.. Journal of Clinical Oncology, 2017, 35, 5015-5015.	0.8	2
346	Patterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease.. Journal of Clinical Oncology, 2017, 35, 8556-8556.	0.8	10
347	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. Journal of Clinical Oncology, 2017, 35, LBA5003-LBA5003.	0.8	2
348	PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.. Journal of Clinical Oncology, 2017, 35, TPS5091-TPS5091.	0.8	10
349	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. Journal of Clinical Oncology, 2017, 35, LBA5003-LBA5003.	0.8	6
350	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.. Journal of Clinical Oncology, 2017, 35, 135-135.	0.8	3
351	Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.. Journal of Clinical Oncology, 2017, 35, 141-141.	0.8	2
352	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget, 2017, 8, 104430-104443.	0.8	5
353	Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. ELife, 2017, 6, .	2.8	32
354	Abstract A08: PARP1-mediated E2F1 regulation of DNA repair capacity. , 2017, , .		0
355	A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.. Journal of Clinical Oncology, 2017, 35, 2573-2573.	0.8	1
356	TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.. Journal of Clinical Oncology, 2017, 35, 2571-2571.	0.8	0
357	A phase 1/1b multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI3726 in patients with metastatic, castration-resistant prostate cancer who have received prior treatment with abiraterone or enzalutamide.. Journal of Clinical Oncology, 2017, 35, TPS5088-TPS5088.	0.8	0
358	Adherence to novel oral anticancer therapies in the phase I setting: The Royal Marsden experience.. Journal of Clinical Oncology, 2017, 35, 2542-2542.	0.8	4
359	Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5014-5014.	0.8	0
360	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.. Journal of Clinical Oncology, 2017, 35, 5071-5071.	0.8	0

#	Article	IF	Citations
361	Abstract LB-044: Copy number estimation from targeted amplicon-based next-generation sequencing of castration-resistant prostate cancer biopsies: analytic validation and clinical qualification for a iPARP clinical trial. , 2017, , .		0
362	Abstract 3807: ATM protein loss and clinical outcomes with platinum chemotherapy in patients with advanced solid tumors. , 2017, , .		0
363	Abstract 2627: A study of dynamic changes in PD-L1 expression inKRASmutant adenocarcinoma of the lung exposed to signal transduction inhibitors. , 2017, , .		0
364	Abstract 1733: Automated identification of circulating tumor cells by image analysis. , 2017, , .		0
365	Abstract LB-085: RB loss-induced genome wide E2F1 reprogramming drive advanced prostate cancer. , 2017, , .		0
366	Abstract 3081: Precision medicine for patients with advanced small cell lung cancer treated with novel therapeutic agents in a phase I clinical trials unit. , 2017, , .		0
367	Abstract LB-086: PARP-1 controls the DNA damage response by regulating E2F1 transcriptional activity. , 2017, , .		0
368	Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. Archivio Italiano Di Urologia Andrologia, 2016, 88, 72.	0.4	0
369	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e577-e583.	1.8	2
370	Abiraterone for the Treatment of mCRPC. , 2016, , 125-155.		0
371	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	13.9	1,205
372	Reply to A. Addeo and A. Bahl. Journal of Clinical Oncology, 2016, 34, 387-388.	0.8	0
373	The â€˜Pushmi-Pullyuâ€™ of DNA REPAIR: Clinical Synthetic Lethality. Trends in Cancer, 2016, 2, 646-656.	3.8	18
374	Targeted Î±-Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?. Journal of Nuclear Medicine, 2016, 57, 1838-1839.	2.8	6
375	Targeting DNA Repair. Cancer Journal (Sudbury, Mass), 2016, 22, 353-356.	1.0	27
376	Visualizing whole-body treatment response heterogeneity using multi-parametric magnetic resonance imaging. Journal of Algorithms and Computational Technology, 2016, 10, 290-301.	0.4	15
377	Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. European Urology Focus, 2016, 2, 488-498.	1.6	38
378	AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate. European Journal of Cancer, 2016, 69, S19.	1.3	1

#	Article	IF	Citations
379	Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. Radiology, 2016, 280, 151-160.	3.6	51
380	Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. Clinical Genitourinary Cancer, 2016, 14, 485-493.	0.9	30
381	Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724â€“31. European Urology, 2016, 70, e170-e171.	0.9	0
382	Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. Cancer Research, 2016, 76, 2731-2742.	0.4	79
383	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. Molecular Cancer Therapeutics, 2016, 15, 1412-1424.	1.9	16
384	Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 599-608.	0.9	111
385	Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development. Journal of Clinical Oncology, 2016, 34, 2431-2432.	0.8	6
386	The Ongoing Challenges of Targeting the Androgen Receptor. European Urology, 2016, 69, 841-843.	0.9	5
387	A study of motivations and expectations of patients seen in phase 1 oncology clinics. Cancer, 2016, 122, 3501-3508.	2.0	24
388	Drug discovery in advanced prostate cancer: translating biology into therapy. Nature Reviews Drug Discovery, 2016, 15, 699-718.	21.5	111
389	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. Journal of Clinical Oncology, 2016, 34, 3005-3013.	0.8	202
390	Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Science Translational Medicine, 2016, 8, 362ps17.	5.8	518
391	A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study. Annals of Oncology, 2016, 27, vi258.	0.6	0
392	CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent. Annals of Oncology, 2016, 27, vi262.	0.6	0
393	Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naÃ¯ve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for â‰¥ 4 years (yrs). Annals of Oncology, 2016, 27, vi251.	0.6	1
394	Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2016, 22, 4280-4282.	3.2	20
395	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. European Urology, 2016, 70, 985-992.	0.9	119
396	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncology, 2016, 2, 471.	3.4	46

#	Article	IF	Citations
397	Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2016, 22, 2874-2884.	3.2	103
398	Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 438-444.	0.9	31
399	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naÃ¯ve Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 675-683.	0.9	70
400	Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents. Drugs, 2016, 76, 421-430.	4.9	4
401	Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. European Journal of Cancer, 2016, 56, 93-100.	1.3	62
402	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 2016, 34, 1402-1418.	0.8	1,089
403	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1652-1659.	0.8	332
404	Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 724-731.	0.9	59
405	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, The, 2016, 387, 1163-1177.	6.3	1,570
406	Chemical or Surgical Castrationâ€"Is This Still an Important Question?. JAMA Oncology, 2016, 2, 437.	3.4	11
407	Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer. JAMA Oncology, 2016, 2, 348.	3.4	155
408	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. European Urology, 2016, 69, 924-932.	0.9	22
409	Prostate cancer. Lancet, The, 2016, 387, 70-82.	6.3	801
410	Abstract 2243: Characterization of PD-L1 expression on circulating tumor cells (CTCs) isolated with a label-free inertial microfluidic system from advanced non-small cell lung cancer patients (NSCLC pts). , 2016, , .		2
411	Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations. Cancer Research, 2016, 76, CT010-CT010.	0.4	11
412	Abstract CT147: Phase I studies of AZD1208, a PIM kinase inhibitor, in patients with recurrent or refractory acute myelogenous leukemia or advanced solid tumors. , 2016, , .		1
413	Safety, efficacy and survival of patients (pts) with primary CNS tumors in phase 1 (Ph1) trials: A 12-year single institution experience.. Journal of Clinical Oncology, 2016, 34, 2043-2043.	0.8	2
414	Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.. Journal of Clinical Oncology, 2016, 34, 2504-2504.	0.8	27

#	Article	IF	Citations
415	Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.. Journal of Clinical Oncology, 2016, 34, 2582-2582.	0.8	5
416	Phase III non-inferiority study of cabazitaxel (C) 20 mg/m² (C20) versus 25 mg/m² (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).. Journal of Clinical Oncology, 2016, 34, 5008-5008.	0.8	34
417	Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5009-5009.	0.8	2
418	Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2016, 34, 5014-5014.	0.8	3
419	Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).. Journal of Clinical Oncology, 2016, 34, 5017-5017.	0.8	10
420	Clinical characteristics of metastatic castration-resistant prostate cancer (mCRPC) patients with DNA repair (DNAr) defects.. Journal of Clinical Oncology, 2016, 34, 5028-5028.	0.8	2
421	High neutrophil-to-lymphocyte ratio (NLR), myeloid-derived suppressor cells (MDSCs) and resistance to corticosteroid therapy (CST) in castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2016, 34, 5076-5076.	0.8	3
422	Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant (ARMOR3-SV).. Journal of Clinical Oncology, 2016, 34, TPS5085-TPS5085.	0.8	2
423	Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL.. Journal of Clinical Oncology, 2016, 34, 182-182.	0.8	1
424	Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.. Journal of Clinical Oncology, 2016, 34, 273-273.	0.8	0
425	PSA levels after dexamethasone withdrawal (DW) in castration resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2016, 34, 278-278.	0.8	0
426	Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.. Journal of Clinical Oncology, 2016, 34, 213-213.	0.8	0
427	Interrogating metastatic prostate cancer treatment switch decisions.. Journal of Clinical Oncology, 2016, 34, 296-296.	0.8	0
428	Loco-regional treatment (LRT) for M1 at diagnosis prostate cancer (PCa) patients (pts) and impact on overall survival (OS): A retrospective analysis.. Journal of Clinical Oncology, 2016, 34, 280-280.	0.8	0
429	Cabazitaxel for the Treatment of Prostate Cancer. , 2016, , 187-214.		0
430	Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302.. Journal of Clinical Oncology, 2016, 34, 168-168.	0.8	0
431	Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.. Journal of Clinical Oncology, 2016, 34, 266-266.	0.8	0
432	Incidence, severity and factors associated with diarrhoea in phase I oncology studies: experience of 1002 consecutive cases.. Journal of Clinical Oncology, 2016, 34, 2568-2568.	0.8	14

#	Article	IF	Citations
433	Clinical outcomes of advanced small cell lung cancer patients (SCLC pts) on phase I (Ph I) trials in the Drug Development Unit (DDU) at the Royal Marsden Hospital (RMH).. Journal of Clinical Oncology, 2016, 34, e14048-e14048.	0.8	0
434	Quantifying patientsâ€™ motivations for phase I oncology trials and how expectations change at the first clinical consultation.. Journal of Clinical Oncology, 2016, 34, 10061-10061.	0.8	0
435	Ultrasound guided biopsies in phase I trials: Single center experience of 350 consecutive cases.. Journal of Clinical Oncology, 2016, 34, 11579-11579.	0.8	0
436	Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.. Journal of Clinical Oncology, 2016, 34, 5062-5062.	0.8	0
437	A phase I study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2571-2571.	0.8	0
438	Target-based therapeutic matching of phase I trials in patients with advanced breast cancer (BC pts) in the Royal Marsden Hospital Drug Development Unit (RMH DDU).. Journal of Clinical Oncology, 2016, 34, 11508-11508.	0.8	0
439	Circulating tumor cell (CTC) rise and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) with low baseline CTC counts.. Journal of Clinical Oncology, 2016, 34, 5042-5042.	0.8	0
440	Clinical and radiological characteristics of metastatic prostate cancer (mPCa) patients (pts) with liver metastases (LM) and association with overall survival (OS).. Journal of Clinical Oncology, 2016, 34, 5043-5043.	0.8	0
441	Abstract 4976: Monitoring CHD1 during prostate cancer progression. , 2016, , .		0
442	Abstract 3099:KRASand clinical context: Differential dynamic signaling output ofKRASmutant lung, colorectal and pancreatic cancer cell lines when exposed to targeted anticancer drugs. , 2016, , .		0
443	Abstract 864: Androgen receptor stability in prostate cancer is regulated by the cochaperone Bag-1L. , 2016, , .		0
444	Abstract 4965: Analytic validation and clinical qualification of a novel immunohistochemical assay for AR-V7 protein expression in metastatic prostate cancer. , 2016, , .		0
445	Abstract 4340: DNA repair genes aberrations in germline DNA in metastatic castration-resistant prostate cancer patients. , 2016, , .		0
446	Abstract 3973: Diffusion-weighted imaging of bone metastases as treatment response biomarker in prostate cancer. , 2016, , .		0
447	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e577-e583.	1.8	0
448	343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts). European Journal of Cancer, 2015, 51, S68.	1.3	2
449	2578 Neutrophil-to-lymphocyte ratio (NLR) in relation to outcome of castration-resistant prostate cancer (CRPC) patients treated with corticosteroids (CS). European Journal of Cancer, 2015, 51, S504.	1.3	0
450	2571 A high baseline neutrophil count may predict poor prognostic outcome in mCRPC: A post-hoc analysis of the TROPIC phase III trial. European Journal of Cancer, 2015, 51, S501.	1.3	0

#	Article	IF	Citations
451	Final quality of life and safety data for patients with metastatic castrationâ€resistant prostate cancer treated with cabazitaxel in the <scp>UK</scp> Early Access Programme (EAP) (<scp>NCT</scp>01254279). BJU International, 2015, 116, 880-887.	1.3	36
452	2550 Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC). European Journal of Cancer, 2015, 51, S493.	1.3	0
453	2558 Impact of PTEN protein loss on response to docetaxel and overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC) patients. European Journal of Cancer, 2015, 51, S496.	1.3	1
454	MP87-18 ASSESSMENT OF CORTICOSTEROID (CS)-ASSOCIATED ADVERSE EVENTS (AES) WITH LONG-TERM (LT) EXPOSURE TO LOW-DOSE PREDNISONE (P) GIVEN WITH ABIRATERONE ACETATE (AA) TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS). Journal of Urology, 2015, 193, .	0.2	2
455	2560 Baseline serum clusterin level in patients with poor prognostic features was associated with response to custirsen treatment: Results from the phase 3 SYNERGY trial of docetaxel +/- custirsen. European Journal of Cancer, 2015, 51, S497.	1.3	0
456	What have we learned from exceptional tumour responses?. Current Opinion in Oncology, 2015, 27, 267-275.	1.1	8
457	SPOP mutation leads to genomic instability in prostate cancer. ELife, 2015, 4, .	2.8	148
458	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	13.5	2,660
459	Impact of Bone-targeted Therapies in Chemotherapy-naÃ¯ve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. European Urology, 2015, 68, 570-577.	0.9	50
460	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer â€“ results of two parallel first-in-human phase I studies. Investigational New Drugs, 2015, 33, 679-690.	1.2	43
461	Sequencing of agents in castration-resistant prostate cancer. Lancet Oncology, The, 2015, 16, e279-e292.	5.1	141
462	PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. British Journal of Cancer, 2015, 113, 1225-1233.	2.9	76
463	Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nature Reviews Urology, 2015, 12, 37-47.	1.9	60
464	First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Panâ€“Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 77-86.	3.2	265
465	PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. European Urology, 2015, 67, 795-802.	0.9	195
466	Reply from Authors re: Camillo Porta, Sergio Bracarda, Romano Danesi. Steroids in Prostate Cancer: The Jury Is Still Out... and Even More Confused. Eur Urol 2015;67:680â€“1. European Urology, 2015, 67, 681-682.	0.9	2
467	Enzalutamide in European and North American men participating in the AFFIRM trial. BJU International, 2015, 115, 41-49.	1.3	13
468	A Randomised Phase 2 Trial of Dexamethasone Versus Prednisolone in Castration-resistant Prostate Cancer. European Urology, 2015, 67, 673-679.	0.9	80

#	Article	IF	Citations
469	Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clinical Cancer Research, 2015, 21, 1621-1627.	3.2	51
470	Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. Journal of Clinical Oncology, 2015, 33, 723-731.	0.8	127
471	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology, The, 2015, 16, 152-160.	5.1	1,100
472	Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK. Clinical Cancer Research, 2015, 21, 739-748.	3.2	121
473	Is there an antiandrogen withdrawal syndrome with enzalutamide?. BJU International, 2015, 115, 373-380.	1.3	34
474	Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Clinical Genitourinary Cancer, 2015, 13, e205-e208.	0.9	28
475	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. Journal of Clinical Oncology, 2015, 33, 1356-1363.	0.8	120
476	Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301. European Urology, 2015, 67, 866-873.	0.9	49
477	Survival with Newly Diagnosed Metastatic Prostate Cancer in the â€œDocetaxel Eraâ€: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European Urology, 2015, 67, 1028-1038.	0.9	340
478	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clinical Cancer Research, 2015, 21, 4586-4596.	3.2	171
479	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Molecular Cell, 2015, 58, 925-934.	4.5	114
480	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncology, The, 2015, 16, 509-521.	5.1	174
481	Higher Risk of Infections with PI3Kâ€“AKTâ€“mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. Clinical Cancer Research, 2015, 21, 1869-1876.	3.2	33
482	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1348-1355.	0.8	343
483	Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors. Clinical Cancer Research, 2015, 21, 1305-1312.	3.2	40
484	Targeting extra-gonadal androgens in castration-resistant prostate cancer. Journal of Steroid Biochemistry and Molecular Biology, 2015, 145, 157-163.	1.2	13
485	The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clinical Cancer Research, 2015, 21, 2297-2304.	3.2	69
486	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clinical Cancer Research, 2015, 21, 3412-3419.	3.2	101

#	Article	IF	Citations
487	Cabozantinibâ€"Getting Under the Skin of Cutaneous Toxicity. JAMA Oncology, 2015, 1, 535.	3.4	7
488	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	13.9	1,796
489	Plasma AR and abiraterone-resistant prostate cancer. Science Translational Medicine, 2015, 7, 312re10.	5.8	366
490	Sarcomatoid carcinoma of the prostate: <scp>ERG</scp> fluorescence inâ€situ hybridization confirms epithelial origin. Histopathology, 2015, 66, 898-901.	1.6	26
491	A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Medicine, 2015, 13, 201.	2.3	14
492	A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castrationâ€Resistant Prostate Cancer. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 277-285.	1.3	23
493	A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. European Journal of Cancer, 2015, 51, 2275-2284.	1.3	25
494	Phase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors. Oncologist, 2015, 20, 368-369.	1.9	5
495	CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer. Clinical Cancer Research, 2015, 21, 4992-4995.	3.2	11
496	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. European Urology, 2015, 67, 310-318.	0.9	35
497	Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. European Urology, 2015, 68, 317-324.	0.9	96
498	Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial. European Urology, 2015, 67, 223-230.	0.9	31
499	Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients. Cancer Research, 2015, 75, CT323-CT323.	0.4	12
500	Abstract CT328: Exploratory genetic analysis of tumors from a phase I/II dose escalation study of GSK2636771 in patients (pts) with PTEN deficient advanced tumors. , 2015, , .		3
501	A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers.. Journal of Clinical Oncology, 2015, 33, 2566-2566.	0.8	5
502	A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC (TF-ADC) in patients with solid tumors.. Journal of Clinical Oncology, 2015, 33, 2570-2570.	0.8	4
503	The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2015, 33, 5000-5000.	0.8	25
504	Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis.. Journal of Clinical Oncology, 2015, 33, 5009-5009.	0.8	14

#	Article	IF	Citations
505	Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials.. Journal of Clinical Oncology, 2015, 33, 5014-5014.	0.8	5
506	Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study).. Journal of Clinical Oncology, 2015, 33, 5035-5035.	0.8	15
507	Enzalutamide (ENZA) in men with chemotherapy-NaÃ¯ve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study.. Journal of Clinical Oncology, 2015, 33, 5036-5036.	0.8	10
508	Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV)â€“Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant.. Journal of Clinical Oncology, 2015, 33, TPS5069-TPS5069.	0.8	3
509	Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. Journal of Clinical Oncology, 2015, 33, 139-139.	0.8	25
510	Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. Journal of Clinical Oncology, 2015, 33, 141-141.	0.8	23
511	Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).. Journal of Clinical Oncology, 2015, 33, 169-169.	0.8	2
512	Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302.. Journal of Clinical Oncology, 2015, 33, 184-184.	0.8	8
513	The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.. Journal of Clinical Oncology, 2015, 33, 187-187.	0.8	5
514	Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel.. Journal of Clinical Oncology, 2015, 33, 215-215.	0.8	3
515	Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.. Journal of Clinical Oncology, 2015, 33, 268-268.	0.8	3
516	Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis.. Journal of Clinical Oncology, 2015, 33, 142-142.	0.8	0
517	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC): PK, safety and PR testing results from the dose escalation cohort.. Journal of Clinical Oncology, 2015, 33, 5051-5051.	0.8	0
518	Clinical outcomes in advanced cervical cancer (CC) and endometrial cancer (EC) patients (pts) treated in phase I trials of novel molecularly targeted agents (MTAs).. Journal of Clinical Oncology, 2015, 33, 5596-5596.	0.8	0
519	Abstract CT138: Translating preclinical observations to the clinic: Combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer. , 2015, , .		1
520	Abstract CT329: Phase I study of the PI3KÎ²/Î´ inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding. , 2015, , .		2
521	Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer. , 2015, , .		2
522	Molecular Characterization and Clinical Utility of Circulating Tumor Cells in the Treatment of Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e197-e203.	1.8	16

#	Article	IF	Citations
523	A Randomised Phase Ii Trial of Dexamethasone Versus Prednisolone in Castration Resistant Prostate Cancer. Annals of Oncology, 2014, 25, iv260.	0.6	1
524	Response Rates and Outcomes with Enzalutamide for Patients with Metastatic Castration Resistant Prostate Cancer and Visceral Disease in the Prevail Trial. Annals of Oncology, 2014, 25, iv262.	0.6	3
525	Analysis of Overall Survival (Os) for Patients (Pts) with Different Prognostic Risk Factors Treated with Cabazitaxel and Prednisone (Cbz + P) After Docetaxel (D) in the Tropic Trial. Annals of Oncology, 2014, 25, iv265.	0.6	0
526	A Phase 1/2 Study of At13387, a Heat Shock Protein 90 (Hsp90) Inhibitor in Combination with Abiraterone Acetate (Aa) and Prednisone (P) in Patients (Pts) with Castration-Resistant Prostate Cancer (Mcrpc) No Longer Responding to Aa. Annals of Oncology, 2014, 25, iv267.	0.6	2
527	Association of Neutrophil-To-Lymphocyte Ratio (Nlr) with Survival (Os) in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients Receiving Prednisone (P) Plus Cabazitaxel (Cbz) or Mitoxantrone (Mtx) in the Tropic Trial. Annals of Oncology, 2014, 25, iv272.	0.6	0
528	Clinical Outcome of Advanced Non-Small Cell Lung Cancer Patients (Ansclc Pts) on Phase I Trials in the Drug Development Unit (Ddu) at the Royal Marsden Hospital (Rmh). Annals of Oncology, 2014, 25, iv434.	0.6	0
529	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. Journal of Clinical Oncology, 2014, 32, 3391-3399.	0.8	110
530	Simple prognostic score for metastatic castrationâ€resistant prostate cancer with incorporation of neutrophilâ€toâ€lymphocyte ratio. Cancer, 2014, 120, 3346-3352.	2.0	128
531	Safety and efficacy of multipolar pulmonary vein ablation catheter vs. irrigated radiofrequency ablation for paroxysmal atrial fibrillation: a randomized multicentre trial. Europace, 2014, 16, 1145-1153.	0.7	48
532	Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers. Clinical Cancer Research, 2014, 20, 5672-5685.	3.2	66
533	Molecular pathology and prostate cancer therapeutics: from biology to bedside. Journal of Pathology, 2014, 232, 178-184.	2.1	34
534	453 Plasma metabolomic signature of novel signal transduction inhibitors from preclinical identification to clinical validation. European Journal of Cancer, 2014, 50, 148-149.	1.3	0
535	A Randomized Phase 3 Study Comparing First-Line Docetaxel/Prednisone (Dp) to Dp Plus Custirsen in Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc). Annals of Oncology, 2014, 25, iv256.	0.6	6
536	Tumor clone dynamics in lethal prostate cancer. Science Translational Medicine, 2014, 6, 254ra125.	5.8	298
537	Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncology, 2014, 10, 219-231.	1.1	30
538	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 1925-1934.	3.2	36
539	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. European Urology, 2014, 66, 799-802.	0.9	56
540	Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. European Journal of Cancer, 2014, 50, 1042-1043.	1.3	0

#	Article	IF	Citations
541	External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone. European Urology, 2014, 66, 8-11.	0.9	21
542	Visceral Disease in Castration-resistant Prostate Cancer. European Urology, 2014, 65, 270-273.	0.9	172
543	MP70-11 IMPACT OF PRIOR ENDOCRINE THERAPY ON CLINICAL BENEFIT OF ABIRATERONE ACETATE IN PATIENTS WITH CHEMOTHERAPY-NAÃVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM COU-AA-302. Journal of Urology, 2014, 191, .	0.2	1
544	PI-05 LATE-BREAKING ABSTRACT: THE PREVAIL STUDY: PRIMARYÂAND NON-VISCERAL / VISCERAL DISEASE SUBGROUPÂRESULTS FOR ENZALUTAMIDE-TREATED MEN WITH METASTATIC PROSTATE CANCER (MPC) THAT HAD PROGRESSED ON ADT. Journal of Urology, 2014, 191, .	0.2	2
545	Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. Gastric Cancer, 2014, 17, 621-629.	2.7	7
546	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. Journal of Hematology and Oncology, 2014, 7, 1.	6.9	156
547	Novel drugs targeting the androgen receptor pathway in prostate cancer. Cancer and Metastasis Reviews, 2014, 33, 567-579.	2.7	29
548	Therapy monitoring of skeletal metastases with whole-body diffusion MRI. Journal of Magnetic Resonance Imaging, 2014, 39, 1049-1078.	1.9	99
549	Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib. Journal of the National Cancer Institute, 2014, 106, dju033.	3.0	59
550	Circulating Tumor Cells: A Multifunctional Biomarker. Clinical Cancer Research, 2014, 20, 2553-2568.	3.2	181
551	Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nature Reviews Clinical Oncology, 2014, 11, 365-376.	12.5	172
552	Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents. Cancer Treatment Reviews, 2014, 40, 170-177.	3.4	39
553	The promise of circulating tumor cell analysis in cancer management. Genome Biology, 2014, 15, 448.	3.8	47
554	Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. British Journal of Cancer, 2014, 111, 2248-2253.	2.9	52
555	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncology, The, 2014, 15, 1147-1156.	5.1	181
556	Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. Cancer and Metastasis Reviews, 2014, 33, 555-566.	2.7	45
557	Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Investigational New Drugs, 2014, 32, 995-1004.	1.2	58
558	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. New England Journal of Medicine, 2014, 371, 424-433.	13.9	2,456

#	Article	IF	Citations
559	PD27-01 EFFICACY AND LONG-TERM SAFETY ANALYSIS OF STUDY COU-AA-302: ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAÃVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.2	0
560	Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. European Urology, 2014, 66, 459-465.	0.9	128
561	Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). European Urology, 2014, 66, 815-825.	0.9	221
562	P623RGS-1 modulates leukocyte trafficking in atherosclerosis and aortic aneurysm formation through chemokine receptor desensitisation. Cardiovascular Research, 2014, 103, S113.1-S113.	1.8	0
563	A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.. Journal of Clinical Oncology, 2014, 32, 2514-2514.	0.8	20
564	TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors.. Journal of Clinical Oncology, 2014, 32, 2607-2607.	0.8	2
565	Phase I dose escalation study of 3-weekly BI 836845, a fully human, affinity optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 2622-2622.	0.8	4
566	Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5007-5007.	0.8	4
567	Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel.. Journal of Clinical Oncology, 2014, 32, 5042-5042.	0.8	2
568	Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo.. Journal of Clinical Oncology, 2014, 32, 5054-5054.	0.8	3
569	Characterization of ovarian cancer long-term responders on olaparib.. Journal of Clinical Oncology, 2014, 32, 5534-5534.	0.8	1
570	Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.. Journal of Clinical Oncology, 2014, 32, 7522-7522.	0.8	22
571	Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719.. Journal of Clinical Oncology, 2014, 32, e13559-e13559.	0.8	3
572	Effect of concomitant medication use on outcomes of treatment and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, e16045-e16045.	0.8	4
573	A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2014, 32, TPS5097-TPS5097.	0.8	3
574	Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.. Journal of Clinical Oncology, 2014, 32, 14-14.	0.8	4
575	Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials.. Journal of Clinical Oncology, 2014, 32, 20-20.	0.8	4
576	Is there an anti-androgen withdrawal effect with enzalutamide?. Journal of Clinical Oncology, 2014, 32, 200-200.	0.8	1

#	Article	IF	Citations
577	CK- and small nuclear size circulating tumor cell (CTCs) phenotypes in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 209-209.	0.8	4
578	Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302.. Journal of Clinical Oncology, 2014, 32, 21-21.	0.8	2
579	Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).. Journal of Clinical Oncology, 2014, 32, 7-7.	0.8	17
580	A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy.. Journal of Clinical Oncology, 2014, 32, 70-70.	0.8	3
581	Sequential monitoring and characterization of circulating tumor cells (CTCs) using the epic sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics.. Journal of Clinical Oncology, 2014, 32, 78-78.	0.8	3
582	Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study.. Journal of Clinical Oncology, 2014, 32, LBA1-LBA1.	0.8	43
583	Reappraisal of glucocorticoids in castrate-resistant prostate cancer. Asian Journal of Andrology, 2014, 16, 666.	0.8	6
584	Phase Iâ€“II Targeted Treatments. Current Clinical Urology, 2014, , 177-186.	0.0	0
585	PARP Inhibitors. Current Clinical Urology, 2014, , 253-264.	0.0	0
586	Predicting positive bone marrow biopsies (BMBs) in patients (PTS) with advanced prostate cancer (APC).. Journal of Clinical Oncology, 2014, 32, 180-180.	0.8	0
587	Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development.. Journal of Clinical Oncology, 2014, 32, 222-222.	0.8	0
588	Primary malignant brain tumours (PMBT) in phase I studies: Barriers to treatment and patient outcomes.. Journal of Clinical Oncology, 2014, 32, 2024-2024.	0.8	0
589	What factors influence advanced ovarian cancer patient (AOC pt) outcomes to phase I trial treatments?. Journal of Clinical Oncology, 2014, 32, 5560-5560.	0.8	0
590	Complications of hyperglycemia in phase 1 trials targeting the PI3K-akt-mTOR (PAM) pathway.. Journal of Clinical Oncology, 2014, 32, 2612-2612.	0.8	0
591	Targeted deep sequencing from circulating plasma DNA as a multipurpose biomarker in pts (pts) referred for phase I trials.. Journal of Clinical Oncology, 2014, 32, 11051-11051.	0.8	0
592	Prognostic significance of the neutrophil-lymphocyte ratio (NLR) in phase 1 clinical trial patients.. Journal of Clinical Oncology, 2014, 32, 3037-3037.	0.8	0
593	Predictive factors of survival for patients with bladder cancer (BC) in phase I clinical trials.. Journal of Clinical Oncology, 2014, 32, e15525-e15525.	0.8	0
594	A study of risk of infection with drugs targeting the PI3 kinase (PI3K), AKT, and mTOR pathway.. Journal of Clinical Oncology, 2014, 32, 2608-2608.	0.8	0

#	Article	IF	Citations
595	Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).. Journal of Clinical Oncology, 2014, 32, 5013-5013.	0.8	0
596	Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302.. Journal of Clinical Oncology, 2014, 32, 5058-5058.	0.8	1
597	Abstract 4819: Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from castrate-resistant prostate cancer (CRPC) patients. , 2014, , .		0
598	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncology, The, 2013, 14, 882-892.	5.1	497
599	New treatment developments applied to elderly patients with advanced prostate cancer. Cancer Treatment Reviews, 2013, 39, 578-583.	3.4	21
600	A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 1041-1050.	1.1	216
601	785 EFFICACY OUTCOMES BY BASELINE PROSTATE-SPECIFIC ANTIGEN (PSA): RESULTS FROM THE PHASE 3 AFFIRM TRIAL. Journal of Urology, 2013, 189, .	0.2	1
602	Appraising iniparib, the PARP inhibitor that never wasâ€"what must we learn?. Nature Reviews Clinical Oncology, 2013, 10, 688-696.	12.5	81
603	Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. Clinical Cancer Research, 2013, 19, 5485-5493.	3.2	126
604	Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways. Journal of Clinical Oncology, 2013, 31, 1592-1605.	0.8	249
605	Management of Patients with Castration-Resistant Disease. Hematology/Oncology Clinics of North America, 2013, 27, 1243-1260.	0.9	2
606	Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 72, 1213-1222.	1.1	15
607	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. New England Journal of Medicine, 2013, 368, 138-148.	13.9	2,412
608	Secondary mutations in <scp>BRCA2</scp> associated with clinical resistance to a <scp>PARP</scp> inhibitor. Journal of Pathology, 2013, 229, 422-429.	2.1	287
609	Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncology, The, 2013, 14, 1307-1316.	5.1	205
610	713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL. Journal of Urology, 2013, 189, .	0.2	1
611	Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. European Urology, 2013, 64, 300-306.	0.9	85
612	715 CABAZITAXEL FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): FINAL QUALITY OF LIFE (QOL) RESULTS WITH SAFETY DATA FROM THE UNITED KINGDOM (UK) EARLY ACCESS PROGRAMME (EAP) (NCT01254279). Journal of Urology, 2013, 189, .	0.2	1

#	Article	IF	Citations
613	Novel Strategies to Test Biological Hypotheses in Early Drug Development for Advanced Prostate Cancer. Clinical Chemistry, 2013, 59, 75-84.	1.5	11
614	Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer. Annual Review of Medicine, 2013, 64, 1-13.	5.0	42
615	Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. European Journal of Cancer, 2013, 49, 3648-3657.	1.3	77
616	Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). Cancer Chemotherapy and Pharmacology, 2013, 72, 909-916.	1.1	20
617	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Investigational New Drugs, 2013, 31, 760-768.	1.2	297
618	First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2013, 19, 5494-5504.	3.2	43
619	Agents That Target Androgen Synthesis in Castration-Resistant Prostate Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 34-42.	1.0	17
620	Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy. Journal of the National Cancer Institute, 2013, 105, 1729-1737.	3.0	150
621	A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma. Clinical Cancer Research, 2013, 19, 900-908.	3.2	112
622	Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy. Journal of Clinical Oncology, 2013, 31, 3944-3950.	0.8	83
623	Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial. Journal of Clinical Oncology, 2013, 31, 2791-2798.	0.8	111
624	A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2013, 19, 4262-4272.	3.2	92
625	Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Annals of Oncology, 2013, 24, 1416-1418.	0.6	62
626	Prostate radiotherapy for men with metastatic disease: a new comparison in the <scp>S</scp>ystemic <scp>T</scp>herapy in <scp>A</scp>dvancing or <scp>M</scp>etastatic <scp>P</scp>rostate <scp>C</scp>ancer: <scp>E</scp>valuation of <scp>D</scp>rug <scp>E</scp>fficacy (<scp>STAMPEDE</scp>) trial. BJU International, 2013, 111, 697-699.	1.3	28
627	Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. Journal of Clinical Pharmacology, 2013, 53, 1020-1027.	1.0	29
628	First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. British Journal of Cancer, 2013, 109, 2579-2586.	2.9	78
629	Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. PLoS ONE, 2013, 8, e67148.	1.1	82
630	Abstract C295: Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.. Molecular Cancer Therapeutics, 2013, 12, C295-C295.	1.9	9

#	Article	IF	Citations
631	Abstract 2433:In vitroandin vivoantitumor activity of the next generation HSP90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models.. , 2013, , .		3
632	First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.. Journal of Clinical Oncology, 2013, 31, 2580-2580.	0.8	50
633	A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2013, 31, 4511-4511.	0.8	7
634	First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2013, 31, 5052-5052.	0.8	2
635	A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC.. Journal of Clinical Oncology, 2013, 31, 123-123.	0.8	3
636	Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phaseÂIII study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, 14-14.	0.8	3
637	Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate.. Journal of Clinical Oncology, 2013, 31, 155-155.	0.8	12
638	Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial.. Journal of Clinical Oncology, 2013, 31, 16-16.	0.8	8
639	Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study.. Journal of Clinical Oncology, 2013, 31, 17-17.	0.8	5
640	Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes.. Journal of Clinical Oncology, 2013, 31, 20-20.	0.8	2
641	Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.. Journal of Clinical Oncology, 2013, 31, 6-6.	0.8	36
642	Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from patients with castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2013, 31, 62-62.	0.8	1
643	Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279).. Journal of Clinical Oncology, 2013, 31, 91-91.	0.8	1
644	Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.. Journal of Clinical Oncology, 2013, 31, LBA8-LBA8.	0.8	30
645	Prognostic value of serum androgens, by ultrasensitive assay, in metastatic castration-resistant prostate cancer (mCRPC): Phase III trial data.. Journal of Clinical Oncology, 2013, 31, 22-22.	0.8	1
646	Outcome of patients (pts) with relapsed, advanced upper gastrointestinal (GI) carcinoma treated in a specialist oncology phase I unit.. Journal of Clinical Oncology, 2013, 31, 45-45.	0.8	0
647	A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.. Journal of Clinical Oncology, 2013, 31, 24-24.	0.8	0
648	Abstract 3517: Changes in plasma components of Î²-oxidation as a pharmacodynamic (PD) biomarker of PI3K inhibition by GDC-0941, a potent, pan-inhibitor of Class I phosphatidyl-inositol-3-kinase (PI3K).. , 2013, , .		0

#	Article	IF	Citations
649	Abstract 3924: Multimodality imaging investigation of response to cabozantinib in a VCaP model of prostate bone metastasis.. , 2013, , .		0
650	Abstract 2341: A study of relationships between signalling output and growth inhibition to personalize combinations of MEK and AKT inhibitors.. , 2013, , .		0
651	Abstract A220: Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors.. , 2013, , .		1
652	Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 507-516.	1.8	234
653	Targeting the DNA damage response in oncology. Current Opinion in Oncology, 2012, 24, 316-324.	1.1	52
654	Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. Annals of Oncology, 2012, 23, 2943-2947.	0.6	224
655	Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Modern Pathology, 2012, 25, 902-910.	2.9	48
656	MDV3100 for the treatment of prostate cancer. Expert Opinion on Investigational Drugs, 2012, 21, 227-233.	1.9	29
657	A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors. Clinical Cancer Research, 2012, 18, 2687-2694.	3.2	66
658	Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Annals of Oncology, 2012, 23, 1241-1249.	0.6	51
659	Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine, 2012, 367, 1187-1197.	13.9	3,847
660	Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncology, The, 2012, 13, 1114-1124.	5.1	125
661	Cabazitaxel in metastatic castration-resistant prostate cancer. Expert Review of Anticancer Therapy, 2012, 12, 1129-1136.	1.1	23
662	Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100. Cancer Research, 2012, 72, 2176-2182.	0.4	240
663	Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. EPMA Journal, 2012, 3, 3.	3.3	23
664	17 The Challenges of Drug Combination Studies. European Journal of Cancer, 2012, 48, 9.	1.3	0
665	The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer. Molecular Cancer Therapeutics, 2012, 11, 1609-1617.	1.9	82
666	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials, 2012, 13, 168.	0.7	121

#	Article	IF	Citations
667	Management of Metastatic Castration-Resistant Prostate Cancer. Drugs, 2012, 72, 1011-1028.	4.9	31
668	PARP Inhibitors. Drugs, 2012, 72, 1579-1590.	4.9	36
669	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology, The, 2012, 13, 983-992.	5.1	1,182
670	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncology, The, 2012, 13, 1210-1217.	5.1	254
671	Therapeutic Options for Advanced Prostate Cancer: 2011 Update. Current Urology Reports, 2012, 13, 170-178.	1.0	13
672	FGF Receptor Inhibitors: Role in Cancer Therapy. Current Oncology Reports, 2012, 14, 111-119.	1.8	51
673	Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. Drug Discovery Today, 2012, 17, 221-226.	3.2	37
674	Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Molecular and Cellular Endocrinology, 2012, 360, 68-75.	1.6	29
675	Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU International, 2012, 110, 658-667.	1.3	16
676	Phase I and pharmacokinetic study of 3â€²-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. Investigational New Drugs, 2012, 30, 316-326.	1.2	8
677	A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy.. Journal of Clinical Oncology, 2012, 30, TPS4693-TPS4693.	0.8	5
678	Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, LBA4518-LBA4518.	0.8	27
679	Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel.. Journal of Clinical Oncology, 2012, 30, 17-17.	0.8	8
680	Flexible trial design in practice: Dropping and adding arms in STAMPEDE (MRC PR08, CRUK/06/019)â€"A multiarm, multistage randomized controlled trial.. Journal of Clinical Oncology, 2012, 30, 27-27.	0.8	1
681	Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279).. Journal of Clinical Oncology, 2012, 30, 44-44.	0.8	4
682	Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. Journal of Clinical Oncology, 2012, 30, LBA1-LBA1.	0.8	66
683	Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers. PLoS ONE, 2012, 7, e47020.	1.1	136
684	Development of a molecular profiling assay for circulating tumor cells (CTCs) utilizing automated multiplexed in situ hybridization for metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 39-39.	0.8	0

#	Article	IF	Citations
685	Prognostic factors for survival in the phase III TROPIC trial.. Journal of Clinical Oncology, 2012, 30, 102-102.	0.8	1
686	Pain control and delay in time to skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA): Long-term follow-up.. Journal of Clinical Oncology, 2012, 30, 183-183.	0.8	0
687	Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy.. Journal of Clinical Oncology, 2012, 30, 4515-4515.	0.8	21
688	Correlation of oncogenic mutations in circulating cell-free DNA (cfDNA) and tumor tissue through a multiplex sequencing platform in patients under consideration for phase I trials.. Journal of Clinical Oncology, 2012, 30, 6-6.	0.8	0
689	Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Expert Opinion on Investigational Drugs, 2011, 20, 1293-1304.	1.9	23
690	The changing therapeutic landscape of castration-resistant prostate cancer. Nature Reviews Clinical Oncology, 2011, 8, 597-610.	12.5	137
691	Abiraterone and Increased Survival in Metastatic Prostate Cancer. New England Journal of Medicine, 2011, 364, 1995-2005.	13.9	3,736
692	Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2011, 17, 3420-3430.	3.2	140
693	7105 POSTER DISCUSSION Belinostat in Combination With Carboplatin and Paclitaxel (BelCaP) for Treatment of Bladder Cancer â€“ A Pharmacokinetic Study of Exposure to Belinostat and Its Metabolites. European Journal of Cancer, 2011, 47, S506.	1.3	4
694	7015 POSTER DISCUSSION Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel â€“ Results From the COU-AA-301 Phase 3 Study. European Journal of Cancer, 2011, 47, S488-S489.	1.3	6
695	New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway. Clinical Cancer Research, 2011, 17, 1649-1657.	3.2	177
696	Utilizing circulating tumor cells: challenges and pitfalls. Current Opinion in Genetics and Development, 2011, 21, 50-58.	1.5	101
697	Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer. European Journal of Cancer, 2011, 47, S189-S194.	1.3	5
698	1234 POSTER A First in Man Phase 1 Study of JNJ-26481585, a Novel Oral Histone Deacetylase Inhibitor (HDACi) in Advanced Cancer Patients -Evidence of Target Modulation, Antitumour Activity and Additional Safety Data in an Expanded Patient Cohort. European Journal of Cancer, 2011, 47, S154-S155.	1.3	0
699	1248 POSTER A Phase I Study Evaluating GDC-0941, a Pan-phosphoinositide-3 Kinase (PI3K) Inhibitor, in Patients (pts) With Advanced Solid Tumours, Multiple Myeloma, and PIK3Ca Mutant (mt) Tumours. European Journal of Cancer, 2011, 47, S159.	1.3	3
700	705 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE, IMPROVES SURVIVAL AND PRODUCES PSA AND RADIOGRAPHIC RESPONSES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY. Journal of Urology, 2011, 185, .	0.2	3
701	Cabazitaxel for castration-resistant prostate cancer â€“ Authors' reply. Lancet, The, 2011, 377, 122-123.	6.3	12
702	First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers. Gynecologic Oncology, 2011, 120, S5-S6.	0.6	2

#	Article	IF	Citations
703	Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. Ca-A Cancer Journal for Clinicians, 2011, 61, 31-49.	157.7	178
704	New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety. European Urology, 2011, 60, 279-290.	0.9	130
705	Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors. Cancer Cell, 2011, 19, 573-574.	7.7	15
706	Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemotherapy and Pharmacology, 2011, 68, 423-429.	1.1	14
707	Flexible trial design in practice â€“ dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. Trials, 2011, 12, .	0.7	10
708	Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castrationâ€resistant prostate cancer. Prostate, 2011, 71, 1264-1275.	1.2	18
709	External quality assurance of circulating tumor cell enumeration using the CellSearch^{Â®} system: A feasibility study. Cytometry Part B - Clinical Cytometry, 2011, 80B, 112-118.	0.7	97
710	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. Clinical Cancer Research, 2011, 17, 5188-5196.	3.2	29
711	A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer. Clinical Cancer Research, 2011, 17, 581-588.	3.2	102
712	Belinostat: clinical applications in solid tumors and lymphoma. Expert Opinion on Investigational Drugs, 2011, 20, 1723-1732.	1.9	34
713	Parallel Anticancer Drug Development and Molecular Stratification to Qualify Predictive Biomarkers: Dealing with Obstacles Hindering Progress. Cancer Discovery, 2011, 1, 207-212.	7.7	18
714	Reporting the Capture Efficiency of a Filter-Based Microdevice: A CTC Is Not a CTC Unless It Is CD45 Negativeâ€"Letter: Figure 1.. Clinical Cancer Research, 2011, 17, 3048-3049.	3.2	18
715	First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2011, 29, 4688-4695.	0.8	506
716	Translating Scientific Advancement into Clinical Benefit for Castration-Resistant Prostate Cancer Patients. Clinical Cancer Research, 2011, 17, 3867-3875.	3.2	53
717	Prostate Cancer: Evolution or Revolution?. Journal of Clinical Oncology, 2011, 29, 3595-3598.	0.8	10
718	Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?. Journal of Clinical Oncology, 2011, 29, 1728-1735.	0.8	120
719	Revisiting the Role of Antiandrogen Strategies in Ovarian Cancer. Oncologist, 2011, 16, 1413-1421.	1.9	19
720	Novel Therapeutic Strategies for Metastatic Prostate Cancer in the Post-Docetaxel Setting. Oncologist, 2011, 16, 1487-1497.	1.9	26

#	Article	IF	Citations
721	Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival. PLoS ONE, 2011, 6, e27419.	1.1	42
722	Abstract 4175: Automated classification of circulating tumor cells optimized using clinical outcome of castration resistant prostate cancer patients. , 2011, , .		0
723	Abstract 3072: Prospective study of genetic mutations in matched tumor and plasma specimens in advanced cancer patients referred to phase I trials. , 2011, , .		0
724	Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemotherapy and Pharmacology, 2010, 65, 765-773.	1.1	169
725	Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. Drug Discovery Today, 2010, 15, 88-97.	3.2	69
726	Translating cancer research into targeted therapeutics. Nature, 2010, 467, 543-549.	13.7	310
727	Envisioning the future of early anticancer drug development. Nature Reviews Cancer, 2010, 10, 514-523.	12.8	262
728	Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate. Journal of Clinical Oncology, 2010, 28, 1489-1495.	0.8	370
729	Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies. Molecular Cancer Therapeutics, 2010, 9, 2447-2449.	1.9	20
730	Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids. Journal of Clinical Oncology, 2010, 28, e560-e561.	0.8	33
731	Targeting the HGF/c-Met Axis: State of Play. Molecular Cancer Therapeutics, 2010, 9, 1077-1079.	1.9	38
732	Reply to J. Veeck et al. Journal of Clinical Oncology, 2010, 28, e565-e566.	0.8	13
733	Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study. Clinical Cancer Research, 2010, 16, 6150-6158.	3.2	94
734	Early oncology clinical trial design in the era of molecular-targeted agents. Future Oncology, 2010, 6, 1339-1352.	1.1	11
735	Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. Journal of Clinical Oncology, 2010, 28, 2512-2519.	0.8	877
736	Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective. European Journal of Cancer, 2010, 46, 9-20.	1.3	108
737	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, The, 2010, 376, 1147-1154.	6.3	2,857
738	Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncology, The, 2010, 11, 129-135.	5.1	334

#	Article	IF	Citations
739	Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2010, 28, 3965-3972.	0.8	332
740	Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 1496-1501.	0.8	396
741	Abstract 788: Correlation of elevated phosphorylated / total AKT ratio, chemoresistance and survival in ovarian cancer ascites samples. , 2010, , .		1
742	Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade. , 2010, , .		0
743	Abstract 1730: Automatic classification of EpCAM+, Cytokeratin+ objects versus survival in castration resistant prostate cancer. , 2010, , .		0
744	Abstract 5440: Study of the mechanism of action and pharmacodynamic response of JNJ-26481585, a potent histone deacetylase inhibitor in the setting of melanoma. , 2010, , .		0
745	Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies.. Blood, 2010, 116, 1787-1787.	0.6	0
746	Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2009, 15, 3177-3183.	3.2	103
747	Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer. Clinical Cancer Research, 2009, 15, 4799-4805.	3.2	324
748	Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven. Cancer Research, 2009, 69, 4937-4940.	0.4	152
749	Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 3742-3748.	0.8	545
750	Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2009, 27, 6152-6159.	0.8	96
751	Quantitative Analysis of Circulating Tumor Cells as a Survival Predictor in Metastatic Castrationâ€“Resistant Prostate Cancer: Missing Parts in a Superb Study. Clinical Cancer Research, 2009, 15, 1504-1505.	3.2	5
752	Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor. Molecular Cancer Therapeutics, 2009, 8, 2077-2078.	1.9	12
753	A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2009, 15, 4978-4985.	3.2	31
754	Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials. Journal of Clinical Oncology, 2009, 27, 2692-2696.	0.8	170
755	Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?. Cancer Cell, 2009, 16, 458-462.	7.7	203
756	A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGIâ„¢), in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2009, 64, 425-429.	1.1	29

#	Article	IF	Citations
757	Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28Âdays in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2009, 65, 167-175.	1.1	2
758	A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for preâ€clinical prostate cancer studies. Prostate, 2009, 69, 1507-1520.	1.2	9
759	From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs. Clinical Pharmacology and Therapeutics, 2009, 85, 131-133.	2.3	32
760	Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers. New England Journal of Medicine, 2009, 361, 123-134.	13.9	3,312
761	168 Circulating tumour cells as biomarkers in clinical trials. European Journal of Cancer, Supplement, 2009, 7, 42-43.	2.2	0
762	1204 A Phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. European Journal of Cancer, Supplement, 2009, 7, 121.	2.2	3
763	1235 A phase-I study of the combination of intravenous reovirus (REOLYSIN Â®) and gemcitabine in patients with advanced cancer. European Journal of Cancer, Supplement, 2009, 7, 131.	2.2	1
764	1255 Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor. European Journal of Cancer, Supplement, 2009, 7, 137.	2.2	1
765	Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer. Cancer Research, 2009, 69, 2912-2918.	0.4	518
766	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncology, The, 2009, 10, 233-239.	5.1	558
767	Biomarker-Driven Early Clinical Trials in Oncology. Cancer Journal (Sudbury, Mass), 2009, 15, 406-420.	1.0	149
768	A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). Journal of Clinical Oncology, 2009, 27, 3503-3503.	0.8	42
769	Pharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies. Journal of Clinical Oncology, 2009, 27, 3507-3507.	0.8	6
770	Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers. Journal of Clinical Oncology, 2009, 27, e14519-e14519.	0.8	2
771	Reovirus: Rationale and clinical trial update. Current Opinion in Molecular Therapeutics, 2009, 11, 532-9.	2.8	25
772	Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemotherapy and Pharmacology, 2008, 62, 911-919.	1.1	37
773	Expression profiling of CD133⁺ and CD133^{â€”} epithelial cells from human prostate. Prostate, 2008, 68, 1007-1024.	1.2	64
774	Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience. British Journal of Cancer, 2008, 99, 1365-1365.	2.9	1

#	Article	IF	Citations
775	Targeting CYP17: established and novel approaches in prostate cancer. Current Opinion in Pharmacology, 2008, 8, 449-457.	1.7	87
776	Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. Current Opinion in Pharmacology, 2008, 8, 359-362.	1.7	29
777	Targeting the PI3Kâ€“AKTâ€“mTOR pathway: progress, pitfalls, and promises. Current Opinion in Pharmacology, 2008, 8, 393-412.	1.7	488
778	Reovirus therapy in cancer: has the orphan virus found a home?. Expert Opinion on Investigational Drugs, 2008, 17, 1925-1935.	1.9	17
779	CYP17 inhibition as a hormonal strategy for prostate cancer. Nature Reviews Urology, 2008, 5, 610-620.	1.4	96
780	Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus. Clinical Cancer Research, 2008, 14, 259-269.	3.2	156
781	A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2008, 14, 2075-2081.	3.2	140
782	Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2008, 14, 6302-6309.	3.2	1,975
783	Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. British Journal of Cancer, 2008, 98, 1029-1033.	2.9	153
784	Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity. Journal of Immunology, 2008, 180, 6018-6026.	0.4	163
785	Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2008, 14, 6663-6673.	3.2	115
786	Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy. Clinical Cancer Research, 2008, 14, 912-923.	3.2	93
787	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. Journal of Clinical Oncology, 2008, 26, 4563-4571.	0.8	819
788	Phase I Dose Escalation Study of the Antiâ€“Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors. Clinical Cancer Research, 2007, 13, 5834-5840.	3.2	246
789	Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 2007, 25, 257-262.	0.8	127
790	Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor. Clinical Cancer Research, 2007, 13, 3611-3616.	3.2	185
791	A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2007, 13, 532-539.	3.2	15
792	Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer. Clinical Cancer Research, 2007, 13, 2675-2683.	3.2	48

#	Article	IF	Citations
793	Pharmacogenomics of Non-Small Cell Lung Cancer. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2007, 5, 228-234.	0.3	0
794	Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology, 2007, 25, 3753-3758.	0.8	63
795	D7-02: Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR. Journal of Thoracic Oncology, 2007, 2, S410.	0.5	12
796	Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers. Clinical Cancer Research, 2007, 13, 6187-6194.	3.2	226
797	703 POSTER A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor. European Journal of Cancer, Supplement, 2007, 5, 108.	2.2	6
798	A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. British Journal of Cancer, 2007, 96, 29-37.	2.9	243
799	Participation of patients with gynecological cancer in phase I clinical trials: Two years experience in a major cancer center. Gynecologic Oncology, 2007, 104, 551-556.	0.6	10
800	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2007, 59, 165-174.	1.1	45
801	Final results of a phase I study of wild-type oncolytic reovirus administered intravenously to patients with advanced cancer. Journal of Clinical Oncology, 2007, 25, 3572-3572.	0.8	3
802	Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC). Journal of Clinical Oncology, 2007, 25, 5135-5135.	0.8	8
803	594: Abiraterone Acetate, an Oral Irreversible Inhibitor of CYP450C17, Administered to Castration Refractory Prostate Cancer Patients is Safe, Suppresses Androgen and Steroid Precursor Levels, and has a High Degree of Durable Antitumor Activity. Journal of Urology, 2007, 177, 199-199.	0.2	0
804	573 POSTER Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumors with mutated EGFR. European Journal of Cancer, Supplement, 2006, 4, 173-174.	2.2	3
805	Update on tubulin-binding agents. Pathologie Et Biologie, 2006, 54, 72-84.	2.2	134
806	Reovirus and other oncolytic viruses for the targeted treatment of cancer. Targeted Oncology, 2006, 1, 130-150.	1.7	11
807	A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2006, 12, 2841-2848.	3.2	6
808	Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU International, 2005, 96, 1241-1246.	1.3	186
809	Clinical anticancer drug development: targeting the cyclin-dependent kinases. British Journal of Cancer, 2005, 92, 7-12.	2.9	94
810	ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas. Clinical Cancer Research, 2004, 10, 7555-7565.	3.2	63

#	Article	IF	Citations
811	The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. Breast Cancer Research, 2003, 5, 154-9.	2.2	41
812	Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. Journal of Clinical Oncology, 2003, 21, 211-222.	0.8	238
813	Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000. Journal of Clinical Oncology, 2003, 21, 203-210.	0.8	39
814	Therapeutics targeting signal transduction for patients with colorectal carcinoma. British Medical Bulletin, 2002, 64, 227-254.	2.7	46
815	Troxacitabine, an l-Stereoisomeric Nucleoside Analog, on a Five-Times-Daily Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology, 2002, 20, 96-109.	0.8	30
816	Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapyâ€"Results From an International Study Group. Journal of Clinical Oncology, 2001, 19, 2647-2657.	0.8	264
817	Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. British Journal of Cancer, 1999, 80, 1786-1791.	2.9	25
818	Granulocyte macrophage colony-stimulating factor and interleukin-3 regulate chemokine and chemokine receptor expression in bone marrow macrophages. Experimental Hematology, 1999, 27, 1735-1745.	0.2	16
819	Selective Tumour Cell Cytotoxicity by Reoviridaeâ€“ Preclinical Evidence and Clinical Trial Results. , 0, , 139-150.		0